- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Germantown Today
By the People, for the People
Head-To-Head Comparison: Senseonics Holdings, Inc. Common Stock and Ralliant
Analysts believe Senseonics Holdings, Inc. Common Stock is more favorable than Ralliant
Mar. 22, 2026 at 2:18pm
Got story updates? Submit your updates here. ›
Ralliant (NYSE:RAL) and Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) are both manufacturing companies, but analysts believe Senseonics Holdings, Inc. Common Stock is more favorable based on its stronger consensus rating and higher potential upside.
Why it matters
This head-to-head comparison provides insights for investors looking to evaluate and choose between these two manufacturing companies as potential investment options.
The details
The analysis compares the two companies across various metrics including top-line revenue, earnings per share, valuation, analyst recommendations, institutional ownership, and profitability. Senseonics Holdings, Inc. Common Stock is seen as having a stronger consensus rating from analysts and a higher potential upside compared to Ralliant.
- The analysis was published on March 22, 2026.
The players
Ralliant
A provider of precision technologies which specializes in designing, developing, manufacturing and servicing precision instruments and engineered products, based in Raleigh, North Carolina.
Senseonics Holdings, Inc. Common Stock
A medical technology company that develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes, headquartered in Germantown, Maryland.
The takeaway
This analysis highlights the key differences between these two manufacturing companies and provides a data-driven perspective on which one analysts believe is the more favorable investment option based on factors like valuation, analyst consensus, and growth potential.

